National Institute for Clinical Excellence sets out new pro-innovation plans
This article was originally published in Clinica
Executive Summary
The UK's National Institute for Health and Clinical Excellence (NICE) has been asked to use health technology assessment (HTA) to inform the NHS of techniques and products that have become obsolete or less clinically and cost-effective than alternatives. In a move that promises a new string to the industry's pro-innovation bow, NICE said it welcomes suggestions for topics.
You may also be interested in...
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
WHO Launches Twin-Track Procedure To Speed Access To Health Products
A procedure used to accelerate the approval of COVID-19 products during the pandemic is to be applied to all medicines using “synchronized and parallel, but otherwise entirely independent, processes,” the World Health Organization says.
England’s NICE Says No To Santhera’s DMD Drug Agamree Due To ‘Unreliable Modeling’
Santhera Pharmaceuticals did not provide enough evidence to demonstrate that its Duchenne muscular dystrophy drug Agamree was a cost-effective use of resources, according to draft guidance from England’s health technology assessment body, NICE.